PennyStockGeneral.com brings you the latest stock market news, alerts, analysis and opinions. Our analysts study all angles of the market to bring you the most up to date information that allows individuals to make informed investment decisions. Today's movers include Cell Therapeutics, Inc (NASDAQ:CTIC), Medisafe 1 Technologies Corp (OTC:MFTH), Transax International Limited (OTC:TNSX), Houston American Energy Corporation (AMEX:HUSA) and Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS).
New York, NY -- (SBWIRE) -- 09/11/2012 -- Shares of Cell Therapeutics, Inc (NASDAQ:CTIC) have risen 27% at midday over optimism prior to its presentation at the annual Rodman & Renshaw Global Investment Conference. The company is scheduled to discuss marketing plans for its non-Hodgkin’s lymphoma drug Pixuvri in the European Union. Cell Therapeutics has a market cap of $34.84 million.
Medisafe 1 Technologies Corp (OTC:MFTH) announced yesterday that they anticipate a special one-off dividend of $0.01 for each common share owned, pending a $7 million perpetual license sale of the company’s technology rights. The perpetual license agreement is anticipated to be signed within 30 days pending the results of a due diligence study by the intended buyer. Details of the third party have not been disclosed.
Shares of Transax International Limited (OTC:TNSX) are trading 566.67% higher to $0.01 at midday, after hitting an intra-day high of $0.024 in the early morning session. Transax has a market capitalization of $960,790. There have been 29.60 million shares traded on the session, compared to a 50-day average of 19,154.
Houston American Energy Corporation (AMEX:HUSA) shares are trading 16.36% higher today following on from yesterday’s 12% rise. The company has recently announced the commencement of drilling operations on its Zorro Gris #1 Well, situated in Colombia. The company’s shares recently traded as low as $1.12, dropping from around $7 one year ago.
Shares of Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) are climbing sharply higher Tuesday, up 37.88% to $3.64 at midday. The company announced that following DSMB recommendations, it will implement a one-time, 225 patient sample size increase to its Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia (AML). They also announced that the DSMB recommendations triggered a $25 million investment into the company. Sunesis has a market capitalization of $171 million.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)